 CAMBRIDGE, Mass. BEIJING--BUSINESS WIRE--- BGNE BTKi--BeiGene, Ltd. NASDAQ: BGNE; HKEX: 06160, a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the U.S. Food and Drug Administration FDA has accepted a supplemental new drug application sNDA for BRUKINSA zanubrutinib for the treatment of adult patients with marginal zone lymphoma MZL who have received at least one prior anti-CD20-based therapy and granted priority revi 